Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...

The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide has made headlines as a US Food and Drug Administration (FDA)–approved treatment for type 2 diabetes (Ozempic) and obesity (Wegovy).

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight ...

Please provide your email address to receive an email when new articles are posted on . At 12 months, 7.1% of patients with AUD and cirrhosis in the naltrexone group vs. 28.6% in the placebo group had ...

Alcohol awareness month in South Carolina is underway, and there are a lot of statsistics that back how much of a problem ...